Telix Pharmaceuticals Limited (TLPPF) Comparison with companies in other sectors?

Telix Pharmaceuticals Limited has a share price of 338.40M. You can analyze Telix Pharmaceuticals Limited (TLPPF) competitors across different market sectors through stock heatmaps.

What are TLPPF's NET and operating margins?

Telix Pharmaceuticals Limited (TLPPF) operating margin is around 0.09, and net profit margin is approximately 0.07 as of the latest reports.

In what way does TLPPF's earnings per share (EPS) trend reflect its financial momentum?

Telix Pharmaceuticals Limited (TLPPF) EPS is 0.09 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Telix Pharmaceuticals Limited is 150.00, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Telix Pharmaceuticals Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Telix Pharmaceuticals Limited like P/E which is 164.24, P/B which is 12.41, and PEG which is 0.39. Compare them with sector averages to evaluate if the stock is priced fairly.

Telix Pharmaceuticals Limited

TLPPF•PNK

Healthcare

Biotechnology

$13.50

$-0.44(-3.18%)

Fundamental Analysis of Telix Pharmaceuticals Limited (TLPPF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.09

P/E Ratio

150.00

ROE

0.14%

Net Margin

0.07%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$4.57B

Shares OutstandingTotal number of shares issued

$338.40M

Book Value/ShareNet worth per share

$1.70

Revenue/ShareAnnual revenue per share

$1.75

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.09

Net MarginNet income as percentage of revenue

7.34%

Operating MarginOperating income as percentage of revenue

9.24%

ROEReturn on shareholders' equity

13.86%

ROAReturn on total assets

2.83%

ROCEReturn on capital employed

4.56%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.07

Cash/ShareCash and equivalents per share

$2.13

FCF YieldFree cash flow as percentage of market cap

0.34%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for TLPPFFinancial Ratios Analysis details for TLPPF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for TLPPFSector Benchmarking details for TLPPF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Telix Pharmaceuticals Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Telix Pharmaceuticals Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Telix Pharmaceuticals Limited's unique business strengths and challenges.

Key Financial Metrics for Telix Pharmaceuticals Limited

For Telix Pharmaceuticals Limited, essential financial indicators include EPS 0.09, PE 150.00, and ROE 0.14. These key ratios reveal insights into Telix Pharmaceuticals Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Telix Pharmaceuticals Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Telix Pharmaceuticals Limited

Metrics like Net Margin 7.34% and ROA 2.83% shed light on how well Telix Pharmaceuticals Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Telix Pharmaceuticals Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Telix Pharmaceuticals Limited

Using ratios such as P/B Ratio 12.41 and PEG Ratio 0.39, investors can assess whether Telix Pharmaceuticals Limited is appropriately valued based on its financials and growth potential. These figures, combined with Telix Pharmaceuticals Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Telix Pharmaceuticals Limited

Financial health indicators, such as Debt/Equity Ratio 1.02 and Cash Flow $0.07, provide a snapshot of Telix Pharmaceuticals Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Telix Pharmaceuticals Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Telix Pharmaceuticals Limited

Investing in Telix Pharmaceuticals Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Telix Pharmaceuticals Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;